Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07195175 · ClinicalTrials.gov registry record · Phase 1

Study of MAR002 in Healthy Men

A Phase 1 study of Acromegaly, sponsored by Marea Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT07195175 is a Phase 1 study of Acromegaly that is actively recruiting participants, run by Marea Therapeutics. The registered enrollment target is 45 participants, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07195175, a Phase 1 study of Acromegaly, is actively recruiting participants, sponsored by Marea Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG MAR002

Study Locations (1)

Arizona

  • Marea Site - Tempe

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-08-11
Est. Completion 2026-07
Phase Phase 1

Sponsor

Marea Therapeutics

3 total trials

What the Registry Record Tells You About NCT07195175

The ClinicalTrials.gov registry entry for NCT07195175 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 13 other Acromegaly trials with a reported enrollment target (54% lower). The listed sponsor is Marea Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07195175 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT07195175 about?

NCT07195175 is a clinical study titled "Study of MAR002 in Healthy Men". Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

What is the current status of trial NCT07195175?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-08-11. Estimated completion is 2026-07.

What conditions does trial NCT07195175 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT07195175?

The interventions under investigation include: Placebo (DRUG), MAR002 (DRUG).

Who is sponsoring clinical trial NCT07195175?

This trial is sponsored by Marea Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07195175 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.